Why the study?
The study aimed to assess the efficacy and safety outcomes of ticagrelor versus clopidogrel in patients with stable coronary artery disease using maximal platelet aggregation and platelet reactivity index methods.
Does ticagrelor reduce platelet reactivity compared to clopidogrel in patients with stable coronary artery disease?
Population
42 patients with stable angina
Comparison
Clopidogrel 75 mg daily vs ticagrelor 90 mg twice daily separated by a 2-week washout
Design
Crossover study
Authors
Loading...
Associated with greater platelet inhibition than clopidogrel in stable CAD; leaves open impact on clinical outcomes.
Does ticagrelor reduce platelet reactivity compared to clopidogrel in patients with stable coronary artery disease?
In patients with stable angina, ticagrelor provides more potent platelet inhibition than clopidogrel as measured by ex vivo platelet reactivity assays.
Feryal Hashim Rada (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: